Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of protein

Nuclear Medicine and Biology

Volumn 33, Issue 4, 2006, Pages 469-480

  Talanov, Vladimir S ^a   Garmestani, Kayhan ^a   Regino, Celeste A S ^a   Milenic, Diane E ^a   Plascjak, Paul S ^b   Waldmann, Thomas A ^a   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Particle; 211At; Astatine; Methyl SAPS; Monoclonal antibody; Radioimmunotherapy; SAPS; SPEMS

Indexed keywords

ANTIBODY CONJUGATE; ASTATINE 211; MONOCLONAL ANTIBODY; N 2 (4 TRIBUTYLSTANNYLPHENETHYL)SUCCINIMIDE; SUCCINIMIDE DERIVATIVE; SUCCINIMIDYL N 2 (4 [ASTATINE 211]ASTATOPHENETHYL) N METHYL SUCCINAMATE; SUCCINIMIDYL N 2 (4 [ASTATINE 211]ASTATOPHENETHYL)SUCCININAMATE; SUCCINIMIDYL N 2 (4 [IODINE 125]IODOPHENETHYL) N METHYL SUCCINAMATE; SUCCINIMIDYL N 2 (4 [IODINE 125]IODOPHENETHYL)SUCCINAMATE; SUCCINIMIDYL N 2 (4 TRIBUTYLSTANNYLPHENETHYL) N METHYL SUCCINAMATE; SUCCINIMIDYL N 2 (4 TRIBUTYLSTANNYLPHENETHYL)SUCCINAMATE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CHEMICAL REACTION; CONJUGATION; DRUG CONJUGATION; DRUG HALF LIFE; DRUG SYNTHESIS; IMMUNOREACTIVITY; IN VIVO STUDY; ISOTOPE LABELING; LINKAGE ANALYSIS; MOUSE; NONHUMAN; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ASTATINE; CELL LINE, TUMOR; COLONIC NEOPLASMS; CROSS-LINKING REAGENTS; DRUG STABILITY; EXCIPIENTS; HUMANS; ISOTOPE LABELING; ISOTOPES; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; ORGAN SPECIFICITY; PROTEIN BINDING; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 33646546009     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.03.001     Document Type: Article

References (33)

1. 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma. Curr Pharm Biotechnol 2 (2001) 341-349
2. Pandit-Taskar N., Hamlin P.A., Reyes S., Larson S.M., and Divgi C.R. New strategies in radioimmunotherapy for lymphoma. Curr Oncol Rep 5 (2003) 364-371
3. 131I-anti-B1 (anti-CD20) antibody. N Engl J Med 329 (1993) 459-465
4. Knox S.J., Goris M.L., Trisler K., Negrim R., Davis T., Liles T.-M., et al. Yttrium-90-labeled anti-CD20 Monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2 (1996) 457-470
5. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet 346 (1995) 336-340
6. Waldmann T.A., White J.D., Carrasquillo J.A., Reynolds J.C., Paik C.H., Gansow O.A., et al. Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 86 (1995) 4063-4075
7. Zhang M., Yao Z., Garmestani K., Axworthy D., Zhang Z., Mallett B., et al. Pretargeting radioimmunotherapy of a murine model of adult T cell leukemia (ATL) with the alpha emitting radionuclide, Bi-213. Blood 100 (2002) 208-216
8. Zhang M., Zhang Z., Garmestani K., Schultz J., Axworthy D.B., Goldman C.K., et al. Pretarget radioimmunotherapy provides effective treatment for lymphoma and leukemia xenografts. Proc Natl Acad Sci U S A 100 (2003) 1891-1895
9. 90Y-DOTA-biotin. Cancer Res 62 (2002) 5755-5760
10. Dadachova E., Nakouzi A., Bryan R.A., and Casadevall A. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci U S A 100 (2003) 10942-10947
11. Miederer M., Seidl C., Beyer G., David E., Charlton D.E., Vranjes-Duric S., et al. Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein. Rad Res 159 (2003) 612-620
12. 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res 62 (2002) 3120-3125
13. Jurcic J.G., Caron P.C., and Scheinberg D.A. Monoclonal antibody therapy of leukemia and lymphoma. In: August J.T., Anders M.W., Murad F., and Coyle J.T. (Eds). Advances in pharmacology vol. 33 (1995), Academic Press, Inc., New York 287-314
14. O'Donoghue J.A., Bardies M., and Wheldon T.E. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36 (1995) 1902-1909
15. Humm J.L., and Cobb L.M. Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med 31 (1990) 75-83
16. McDevitt M.R., Sgouros G., Finn R.D., Humm J.L., Jurcic J.G., Larson S.M., et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 25 (1998) 1341-1351
17. Zalutsky M.R., and Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Design 6 (2000) 1433-1455
18. Milenic D.E., Brady E.D., and Brechbiel M.W. Antibody targeted radiation cancer therapy. Nat Rev Drug Discov 3 (2004) 488-498
19. Aaij C., Tschroots W.R.J.M., Lindner L., and Feltkamp T.E.W. The preparation of astatine labelled proteins. Int J Appl Radiat Isot 26 (1975) 25-30
20. Vaughan A.T.M., and Fremlin J.H. The preparation of astatine labelled proteins using an electrophilic reaction. Int J Nucl Med Biol 5 (1978) 229-230
21. 2 fragment. Cancer Res 50 (1990) 3514-3520
22. Garg P.K., Garg S., and Zalutsky M.R. N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies. Nucl Med Biol 20 (1993) 379-387
23. 211At-IgG conjugate which is stable in vivo. Int J Appl Radiat Isot 35 (1984) 1005-1008
24. 2 fragments with the α-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci U S A 86 (1989) 7149-7153
25. Zalutsky M.R., Stabin M.G., Larsen R.H., and Bigner D.D. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an α-particle-emitting immunoconjugate. Nucl Med Biol 24 (1997) 255-261
26. 211At labeling of humanized Anti-Tac. Nucl Med Biol 28 (2001) 845-856
27. 211At labeling of proteins. Nucl Med Biol 31 (2004) 1061-1071
28. 211At produced in disposable internal and external bismuth targets. Nucl Med Biol 25 (1998) 89-93
29. De Darlo F., and Ranzi G. 2-Methylisoxazolin-5-ones. Part II: ring-opening by bases. Tetrahedron 22 (1966) 2995-2999
30. 111In labeled Herceptin. Nucl Med Biol 29 (2002) 599-606
31. Tom R.H., Rutzky L.H., and Jakstys M.H. Human colonic adenocarcinoma cells. Establishment and description of a new cell line. In Vitro 12 (1976) 180-191
32. Colcher D., Keenan A.M., Larson S.M., and Schlom J. Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. Cancer Res 44 (1984) 5744-5781
33. Safavy A., Georg G.I., Velde D.V., Raisch K.P., Safavy K., Carpenter M., et al. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure. Bioconjugate Chem 15 (2004) 1264-1274